“Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S36. doi:10.25251/skin.3.supp.36.